Navigation Links
Veracyte Appoints Mark Spring as Chief Financial Officer
Date:1/31/2012

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2012 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Mark Spring as chief financial officer.

"We are delighted that Mark Spring has joined the Veracyte team," said Bonnie Anderson, Veracyte's cofounder and chief executive officer. "His extensive experience as a CFO and senior finance leader in both public and private healthcare companies will be key as we execute against our vision of developing and commercializing molecular cytology tests that enable physicians to make more informed treatment decisions that improve patient care and provide cost savings to the healthcare system."

Mr. Spring has more than 17 years of experience in senior finance roles with leading healthcare companies. He previously served as senior vice president and CFO for Promethius Laboratories Inc., a privately held diagnostic and specialty pharmaceutical company with over $500 million in revenues, which was sold to Nestle S.A. in 2011. Prior to that, he was senior vice president and CFO at Hyperion Therapeutics, Inc. and was also vice president of finance and controller at MedImmune, which was acquired by AstraZeneca in 2007. Mr. Spring has also held senior finance roles with Baxter International, Dade Behring, Caremark International Inc. and PricewaterhouseCoopers.

"I am extremely pleased to join the top-notch management team of this exciting company," said Mr. Spring of Veracyte. "In just three years, Veracyte has successfully developed and launched its first product – the Afirma® Thyroid FNA Analysis, for improved thyroid nodule diagnosis. In the first year of commercialization, the Veracyte team has achieved Medicare coverage and established a global co-promotion partnership with Genzyme, one of the world's leading biotechnology companies. I'm excited to support the company's continued commercial growth and the development of additional genomic tests that serve unmet clinical needs in other disease areas."

About the Afirma Thyroid FNA Analysis
Veracyte's Afirma Thyroid FNA Analysis is designed to improve thyroid nodule diagnosis. This novel solution combines expert cytopathology assessment of thyroid nodule fine needle aspiration (FNA) samples with the company's Afirma Gene Expression Classifier, a genomic test used to clarify inconclusive results as benign or suspicious for cancer, and thus help patients avoid unnecessary surgery if their nodules are actually benign. Two independent clinical studies have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

Thyroid cancer is the fastest-growing cancer in the U.S., with an estimated 56,460 new cases expected in 2012, according to the American Cancer Society. An estimated 450,000 thyroid nodule fine needle aspirations (FNAs) – a minimally invasive procedure to extract suspicious cells for examination under a microscope – are performed in the U.S. each year to rule out cancer. Thyroid nodule FNAs are challenging to interpret, however, producing ambiguous results in up to 30 percent of cases. Current guidelines recommend that most of these patients undergo thyroid resection for a definitive diagnosis, given that thyroid cancer is highly treatable. Post-surgical results, however, show that only 20-30 percent of these patients have cancer.

About Veracyte
Veracyte, Inc., based in South San Francisco, Calif., is pioneering the emerging field of molecular cytology, applying molecular biomarkers to cytology samples in order to improve disease diagnosis by clarifying indeterminate results obtained from current methods. The company aims to enable doctors to make more informed treatment decisions that improve patient care and provide cost savings to the healthcare system. The company utilizes rigorous science and an extensive, multicenter clinical program throughout discovery and development. Veracyte's first product – the Afirma Thyroid FNA Analysis – combines expert cytopathology assessment with the Afirma Gene Expression Classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer. The company is currently in the early biomarker discovery phase for lung cancer and interstitial lung diseases. Veracyte is privately held and funded by Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures. For more information, visit www.veracyte.com.


'/>"/>
SOURCE Veracyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
2. New Data Suggest Veracytes Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results
3. New Data Suggest Veracytes Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
4. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
5. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
6. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
9. BioStorage Technologies Appoints New Member to Board of Directors
10. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
11. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):